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MMF
(n¼117)
Placebo
(n¼119)
P value
GvHD free survival at
day 56
61% (52-70%) 52% (43-61%) 0.78 *
CGvHD at 6 mo 24% (16-32%) 27% (18-35%) 0.69 y
Non relapse mortality
at 6 mo
16% (9-22%) 20% (13-28%) 0.83 y
Overall survival at 6 mo 71% (62-79%) 74% (65-81%) 0.25z
* Chi-square test.
y Gray's test.
z Log-rank test.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149 S137with cGVHD may amplify subsequent BCR-signaling and
contribute to the pathophysiology of cGVHD. Thus, small
molecule inhibitors of Syk may represent a potential thera-
peutic option for patients with cGVHD.
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Steroids are accepted standard primary therapy for
aGvHD, but durable responses are infrequent. A prior trial
conducted by the BMT CTN (0302) tested the addition of 1 of
4 agents to steroids as initial therapy and found mycophe-
nolate mofetil (MMF) to be the most promising for further
investigation. In this context, a phase III, multi-center
randomized trial BMT CTN 0802, sponsored by the NHLBI
and NCI, was initiated to test the addition of MMF/placebo to
steroids as initial therapy for aGvHD. Patients with any grade
of newly diagnosed aGvHD were eligible if they required
systemic therapy. The primary study objective was GvHD
free survival at day 56 after initiation of therapy. All patients
received prednisone at 2 mg/kg/day (or equivalent) with
either MMF (1000mg PO/IV q8h or 20 mg/kg for patients
<60kg) or placebo. Taper of steroids was allowed no sooner
than 3 days into study therapy, at the discretion of the
treating physician, but the protocol required treatment with
prednisone at a dose of at least 0.25 mg/kg/day of prednisone
until day 28. MMFwas continued until day 56 or until steroid
discontinuation if sooner. Patients who developed aGvHD
while on MMF prophylaxis or after unplanned DLI were
excluded. Patients who had previously received MMF for
prophylaxis were eligible if they had not received any MMF
in the previous week. All patients needed to be engrafted.
The study speciﬁed a futility rule for GVHD free survival at
day 56 and the rule was met at a planned interim analysis
after 236 patients (out of 372) were enrolled from 36 centers:
117 toMMF,119 to placebo. Baseline characteristics werewell
balanced between treatment groups. Grade of GvHD atrandomizationwas I/II (65%), III (28%) and IV (6%). GvHD free
survival at day 56 after randomization was: MMF 69 pts
(60.5%; 95% CI 51.6-69.5), placebo 60 pts (52.2%; 95% CI 43.0-
61.3) P ¼ .78. Chronic GvHD developed in 38 patients on
MMF: 6 month (mo) estimate: 23.7% (95% CI 15.9-31.6), and
39 patients on placebo: 6 mo estimate: 26.5% (95% CI 18.3-
34.7) P ¼ .69. Overall survival at 6 mo, EBV reactivation,
cumulative incidence of severe, life threatening, or fatal
infections were similar. Cytopenias were more common in
the MMF arm, while hyperglycemia was more common in
the placebo arm. Cumulative incidence estimates for non
relapse mortality at 6 mo was similar in both arms: MMF
15.5% vs. placebo 20.1%. p¼0.83. Estimated 6 mo overall
survival was 71.3% forMMFand 73.8% for placebo P¼ .25. The
addition of MMF to steroids as ﬁrst line therapy for patients
with aGvHD does not result in improved GvHD free survival
compared to treatment with steroids alone.
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Atorvastatin (ATOR) is a potent immunomodulatory agent
that holds promise as a novel and safe agent for aGVHD
prophylaxis. In murine models ATOR administration to both
donor and recipient mice, prevented aGVHD by inhibiting
donor T-cell proliferation, inducing TH-2 polarization, and by
inhibiting recipient antigen presenting cell function.
We conducted a phase II study (NCT01175148) to evaluate
the safety and efﬁcacy of ATOR administration for aGVHD
prophylaxis, to both adult donors and recipients of MRD
alloHCT. As aGVHD prophylaxis, ATOR (40mg/day PO) was
administered to sibling donors, starting 14-28 days before
the anticipated 1st day of stem cell collection. In alloHCT
recipients aGVHD prophylaxis consisted of tacrolimus,
micro-dose methotrexate and ATOR (40mg/day) adminis-
tered from day -14 to day +180. Ex vivo or in vivo T-cell
depletion was not permitted. Primary outcomes were rate of
grade (Gr) II-IV aGVHD at day 100 and safety of ATOR
administration to alloHCT donors/recipients. We tested the
null hypothesis H0: p35%, vs. the alternate H1: p15%;
where p is the probability of Gr II-IV aGVHD at day 100.
